Modelling the Immune Response to Cancer: An Individual-Based Approach Accounting for the Difference in Movement Between Inactive and Activated T Cells
暂无分享,去创建一个
Tommaso Lorenzi | Mark A. J. Chaplain | Fiona R Macfarlane | T. Lorenzi | M. Chaplain | Fiona R. Macfarlane | Mark A J Chaplain
[1] A. Molinaro,et al. A preliminary mathematical model of skin dendritic cell trafficking and induction of T cell immunity , 2009 .
[2] Fenghua Wang,et al. In Silico Synergism and Antagonism of an Anti-tumour System Intervened by Coupling Immunotherapy and Chemotherapy: A Mathematical Modelling Approach , 2011, Bulletin of Mathematical Biology.
[3] Rebecca H. Chisholm,et al. Mathematical model reveals how regulating the three phases of T‐cell response could counteract immune evasion , 2015, Immunology.
[4] R. Yasuda,et al. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy , 2003, Cancer Immunology, Immunotherapy.
[5] M. Donia,et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen , 2016, Clinical Cancer Research.
[6] E. Mardis,et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.
[7] Frederic Bartumeus,et al. Stochastic Optimal Foraging: Tuning Intensive and Extensive Dynamics in Random Searches , 2014, PloS one.
[8] Hiroaki Ikeda,et al. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. , 2016, International immunology.
[9] Matthew J. Frigault,et al. Chimeric antigen receptor-modified T cells strike back. , 2016, International immunology.
[10] Alberto d'Onofrio,et al. Simple biophysical model of tumor evasion from immune system control. , 2011, Physical review. E, Statistical, nonlinear, and soft matter physics.
[11] F. Garrido,et al. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.
[12] Z. Eshhar,et al. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. , 2016, Annual review of pharmacology and toxicology.
[13] W. Oyen,et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. , 2013, Cancer research.
[14] Y. Bae,et al. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors , 2007, Cancer Immunology, Immunotherapy.
[15] Peter Friedl,et al. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. , 2003, Blood.
[16] Badal Joshi,et al. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. , 2009, Journal of theoretical biology.
[17] Mikala Egeblad,et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.
[18] Frederic Bartumeus,et al. T cell migration, search strategies and mechanisms , 2016, Nature Reviews Immunology.
[19] Carlo Cattani,et al. Metamodeling the learning-hiding competition between tumours and the immune system: A kinematic approach , 2010, Math. Comput. Model..
[20] Sebastian Amigorena,et al. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.
[21] G. D. Knott,et al. Modeling tumor regrowth and immunotherapy , 2001 .
[22] S. Spranger. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. , 2016, International immunology.
[23] L. Zitvogel,et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] D. Stauffer,et al. A discrete model for immune surveillance, tumor immunity and cancer. , 1991, Journal of theoretical biology.
[25] Philip Hahnfeldt,et al. Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion , 2013, Interface Focus.
[26] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[27] G. Prendergast,et al. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. , 2016, The oncologist.
[28] Ramon Arens,et al. In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity , 2016, Immunity.
[29] Weiyang Jin,et al. Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing , 2016, Cell.
[30] Arancha Casal,et al. Agent-based modeling of the context dependency in T cell recognition. , 2005, Journal of theoretical biology.
[31] Gil Ariel,et al. Swarming bacteria migrate by Lévy Walk , 2015, Nature Communications.
[32] P. Agostinis,et al. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. , 2017, Trends in immunology.
[33] Azuma Ohuchi,et al. A Mathematical Analysis of the Interactions between Immunogenic Tumor Cells and Cytotoxic T Lymphocytes , 2001, Microbiology and immunology.
[34] Grant Lythe,et al. How many dendritic cells are required to initiate a T-cell response? , 2012, Blood.
[35] L. Butterfield. Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress? , 2013, Front. Immunol..
[36] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[37] D. G. Mallet,et al. Spatial tumor-immune modeling , 2006 .
[38] Marcello Edoardo Delitala,et al. Recognition and learning in a mathematical model for immune response against cancer , 2013 .
[39] Nicola Bellomo,et al. From the mathematical kinetic, and stochastic game theory to modelling mutations, onset, progression and immune competition of cancer cells ✩ , 2008 .
[40] F. Detcheverry. Generalized run-and-turn motions: From bacteria to Lévy walks. , 2017, Physical review. E.
[41] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[42] Kerry A Landman,et al. A dynamical model of tumour immunotherapy. , 2014, Mathematical biosciences.
[43] B. Neyns,et al. Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma , 2011, Journal of immunotherapy.
[44] M. Chaplain,et al. Evasion of tumours from the control of the immune system: consequences of brief encounters , 2012, Biology Direct.
[45] Wolfgang Weninger,et al. Leukocyte migration in the interstitial space of non-lymphoid organs , 2014, Nature Reviews Immunology.
[46] D. Cockcroft,et al. Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated regulatory dendritic cells. , 2010, American journal of respiratory cell and molecular biology.
[47] P. Hersey,et al. How melanoma cells evade trail-induced apoptosis , 2001, Nature Reviews Cancer.
[48] P. Mainwaring,et al. A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer , 2015, Journal of immunotherapy.
[49] Marina E. Wosniack,et al. The evolutionary origins of Lévy walk foraging , 2017, PLoS Comput. Biol..
[50] Salvatore Musumeci,et al. Modeling immune system control of atherogenesis , 2008, Bioinform..
[51] B. Neyns,et al. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Tres,et al. Dendritic cell uptake of iron‐based magnetic nanoparticles , 2008, Cell biology international.
[53] Mark A J Chaplain,et al. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.
[54] J. E. Brewer,et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells , 2015, Clinical and experimental immunology.
[55] Y. Bae,et al. Dendritic cell-based therapeutic cancer vaccines: past, present and future , 2014, Clinical and experimental vaccine research.
[56] Ferdinando Chiacchio,et al. Mathematical modeling of the immune system recognition to mammary carcinoma antigen , 2012, BMC Bioinformatics.
[57] C. Figdor,et al. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells , 2015, Clinical Cancer Research.
[58] G. Coukos,et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes , 2011, Journal of Translational Medicine.
[59] P. Cattiaux,et al. A Biased Competition Theory of Cytotoxic T Lymphocyte Interaction with Tumor Nodules , 2015, PloS one.
[60] Andrea J. Liu,et al. Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells , 2012, Nature.
[61] J. Modiano,et al. Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth? , 2016, Discovery medicine.
[62] Melanie E. Moses,et al. Persistence and Adaptation in Immunity: T Cells Balance the Extent and Thoroughness of Search , 2016, PLoS Comput. Biol..
[63] S. Abrams,et al. How tumours escape mass destruction , 2008, Oncogene.
[64] Svetlana Bunimovich-Mendrazitsky,et al. Mathematical Model of Pulsed Immunotherapy for Superficial Bladder Cancer , 2008, Bulletin of mathematical biology.
[65] Mikhail Kolev,et al. Mathematical modeling of the competition between acquired immunity and cancer , 2003 .